Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors.

Axford LC, Agarwal PK, Anderson KH, Andrau LN, Atherall J, Barker S, Bennett JM, Blair M, Collins I, Czaplewski LG, Davies DT, Gannon CT, Kumar D, Lancett P, Logan A, Lunniss CJ, Mitchell DR, Offermann DA, Palmer JT, Palmer N, Pitt GR, Pommier S, Price D, Narasinga Rao B, Saxena R, Shukla T, Singh AK, Singh M, Srivastava A, Steele C, Stokes NR, Thomaides-Brears HB, Tyndall EM, Watson D, Haydon DJ.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6598-603. doi: 10.1016/j.bmcl.2013.10.058. Epub 2013 Nov 4.

PMID:
24239017
2.

Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.

Gjorgjieva M, Tomašič T, Barančokova M, Katsamakas S, Ilaš J, Tammela P, Peterlin Mašič L, Kikelj D.

J Med Chem. 2016 Oct 13;59(19):8941-8954. Epub 2016 Sep 20.

PMID:
27541007
3.

Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.

Werner MM, Patel BA, Talele TT, Ashby CR, Li Z, Zauhar RJ.

Bioorg Med Chem. 2015 Sep 15;23(18):6125-37. doi: 10.1016/j.bmc.2015.08.004. Epub 2015 Aug 14.

PMID:
26320664
4.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mitton-Fry MJ, Brickner SJ, Hamel JC, Brennan L, Casavant JM, Chen M, Chen T, Ding X, Driscoll J, Hardink J, Hoang T, Hua E, Huband MD, Maloney M, Marfat A, McCurdy SP, McLeod D, Plotkin M, Reilly U, Robinson S, Schafer J, Shepard RM, Smith JF, Stone GG, Subramanyam C, Yoon K, Yuan W, Zaniewski RP, Zook C.

Bioorg Med Chem Lett. 2013 May 15;23(10):2955-61. doi: 10.1016/j.bmcl.2013.03.047. Epub 2013 Mar 21.

PMID:
23566517
5.

Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus.

Phillips JW, Goetz MA, Smith SK, Zink DL, Polishook J, Onishi R, Salowe S, Wiltsie J, Allocco J, Sigmund J, Dorso K, Lee S, Skwish S, de la Cruz M, Martín J, Vicente F, Genilloud O, Lu J, Painter RE, Young K, Overbye K, Donald RG, Singh SB.

Chem Biol. 2011 Aug 26;18(8):955-65. doi: 10.1016/j.chembiol.2011.06.011.

6.

Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.

Tomašič T, Katsamakas S, Hodnik Ž, Ilaš J, Brvar M, Solmajer T, Montalvão S, Tammela P, Banjanac M, Ergović G, Anderluh M, Peterlin Mašič L, Kikelj D.

J Med Chem. 2015 Jul 23;58(14):5501-21. doi: 10.1021/acs.jmedchem.5b00489. Epub 2015 Jul 8.

PMID:
26098163
7.

Synthesis, characterization, theoretical, anti-bacterial and molecular docking studies of quinoline based chalcones as a DNA gyrase inhibitor.

Abdullah MI, Mahmood A, Madni M, Masood S, Kashif M.

Bioorg Chem. 2014 Jun;54:31-7. doi: 10.1016/j.bioorg.2014.03.006. Epub 2014 Mar 29.

PMID:
24747187
8.

Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.

Stokes NR, Thomaides-Brears HB, Barker S, Bennett JM, Berry J, Collins I, Czaplewski LG, Gamble V, Lancett P, Logan A, Lunniss CJ, Peasley H, Pommier S, Price D, Smee C, Haydon DJ.

Antimicrob Agents Chemother. 2013 Dec;57(12):5977-86. doi: 10.1128/AAC.00719-13. Epub 2013 Sep 16.

9.

Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

Tari LW, Li X, Trzoss M, Bensen DC, Chen Z, Lam T, Zhang J, Lee SJ, Hough G, Phillipson D, Akers-Rodriguez S, Cunningham ML, Kwan BP, Nelson KJ, Castellano A, Locke JB, Brown-Driver V, Murphy TM, Ong VS, Pillar CM, Shinabarger DL, Nix J, Lightstone FC, Wong SE, Nguyen TB, Shaw KJ, Finn J.

PLoS One. 2013 Dec 26;8(12):e84409. doi: 10.1371/journal.pone.0084409. eCollection 2013.

10.

Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.

Surivet JP, Zumbrunn C, Rueedi G, Hubschwerlen C, Bur D, Bruyère T, Locher H, Ritz D, Keck W, Seiler P, Kohl C, Gauvin JC, Mirre A, Kaegi V, Dos Santos M, Gaertner M, Delers J, Enderlin-Paput M, Boehme M.

J Med Chem. 2013 Sep 26;56(18):7396-415. doi: 10.1021/jm400963y. Epub 2013 Sep 11.

PMID:
23968485
11.

Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.

Jakopin Ž, Ilaš J, Barančoková M, Brvar M, Tammela P, Sollner Dolenc M, Tomašič T, Kikelj D.

Eur J Med Chem. 2017 Apr 21;130:171-184. doi: 10.1016/j.ejmech.2017.02.046. Epub 2017 Feb 22.

PMID:
28246042
12.

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.

Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Nelson K, Brown-Driver V, Castellano A, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Finn J, Tari LW.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1537-43. doi: 10.1016/j.bmcl.2012.11.073. Epub 2012 Dec 8.

PMID:
23294697
13.

Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors.

Paneth A, Stączek P, Plech T, Strzelczyk A, Dzitko K, Wujec M, Kuśmierz E, Kosikowska U, Grzegorczyk A, Paneth P.

J Enzyme Inhib Med Chem. 2016;31(1):14-22. doi: 10.3109/14756366.2014.1003214. Epub 2015 Sep 4.

PMID:
25792505
14.

Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.

Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE.

J Med Chem. 2013 Nov 14;56(21):8712-35. doi: 10.1021/jm401208b. Epub 2013 Oct 29.

PMID:
24098982
15.

Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.

Tanitame A, Oyamada Y, Ofuji K, Fujimoto M, Iwai N, Hiyama Y, Suzuki K, Ito H, Terauchi H, Kawasaki M, Nagai K, Wachi M, Yamagishi J.

J Med Chem. 2004 Jul 1;47(14):3693-6.

PMID:
15214796
16.

Discovery and in vivo evaluation of alcohol-containing benzothiazoles as potent dual-targeting bacterial DNA supercoiling inhibitors.

Palmer JT, Axford LC, Barker S, Bennett JM, Blair M, Collins I, Davies DT, Ford L, Gannon CT, Lancett P, Logan A, Lunniss CJ, Morton CJ, Offermann DA, Pitt GR, Rao BN, Singh AK, Shukla T, Srivastava A, Stokes NR, Thomaides-Brears HB, Yadav A, Haydon DJ.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4215-22. doi: 10.1016/j.bmcl.2014.07.037. Epub 2014 Jul 19.

PMID:
25086682
17.

Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.

Alt S, Mitchenall LA, Maxwell A, Heide L.

J Antimicrob Chemother. 2011 Sep;66(9):2061-9. doi: 10.1093/jac/dkr247. Epub 2011 Jun 21.

PMID:
21693461
18.

Synthesis, and antibacterial activity of novel 4,5-dihydro-1H-pyrazole derivatives as DNA gyrase inhibitors.

Liu JJ, Sun J, Fang YB, Yang YA, Jiao RH, Zhu HL.

Org Biomol Chem. 2014 Feb 14;12(6):998-1008. doi: 10.1039/c3ob41953c.

PMID:
24382549
19.

Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: structure based design, synthesis, SAR and antimicrobial activity.

Yule IA, Czaplewski LG, Pommier S, Davies DT, Narramore SK, Fishwick CW.

Eur J Med Chem. 2014 Oct 30;86:31-8. doi: 10.1016/j.ejmech.2014.08.025. Epub 2014 Aug 7.

PMID:
25137573
20.

Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB.

Mesleh MF, Cross JB, Zhang J, Kahmann J, Andersen OA, Barker J, Cheng RK, Felicetti B, Wood M, Hadfield AT, Scheich C, Moy TI, Yang Q, Shotwell J, Nguyen K, Lippa B, Dolle R, Ryan MD.

Bioorg Med Chem Lett. 2016 Feb 15;26(4):1314-8. doi: 10.1016/j.bmcl.2016.01.009. Epub 2016 Jan 6.

PMID:
26786695

Supplemental Content

Support Center